Is BHST or SRZN more profitable?

BioHarvest Sciences has a net margin of -32.54% compared to Surrozen's net margin of -4,810.50%. BioHarvest Sciences' return on equity of -76.03% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets BioHarvest Sciences -32.54% -76.03% -25.30% Surrozen -4,810.50% -4,055.04% -154.08%

Do analysts prefer NLTX or BHST?

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 212.50%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioHarvest Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

BioHarvest Sciences (BHST) Competitors

$3.20 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.26 +0.06 (+2.03%)

As of 06/12/2026 04:10 PM Eastern

Compare

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

Should you buy BioHarvest Sciences stock or one of its competitors? MarketBeat compares BioHarvest Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioHarvest Sciences include Surrozen (SRZN), Neoleukin Therapeutics (NLTX), MacroGenics (MGNX), Entrada Therapeutics (TRDA), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry.

How does BioHarvest Sciences compare to Surrozen?

BioHarvest Sciences (NASDAQ:BHST) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

BioHarvest Sciences currently has a consensus price target of $10.00, indicating a potential upside of 212.50%. Surrozen has a consensus price target of $42.00, indicating a potential upside of 79.56%. Given BioHarvest Sciences' higher possible upside, research analysts clearly believe BioHarvest Sciences is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

BioHarvest Sciences has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

In the previous week, Surrozen had 3 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Surrozen and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Surrozen's score of 0.93 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
BioHarvest Sciences	Very Positive
Surrozen	Positive

BioHarvest Sciences has higher revenue and earnings than Surrozen. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.79	-$11.14M	-$0.59	N/A
Surrozen	$7.49M	36.24	-$242.03M	-$37.59	N/A

66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioHarvest Sciences has a net margin of -32.54% compared to Surrozen's net margin of -4,810.50%. BioHarvest Sciences' return on equity of -76.03% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Surrozen	-4,810.50%	-4,055.04%	-154.08%

Summary

BioHarvest Sciences beats Surrozen on 9 of the 17 factors compared between the two stocks.

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

BioHarvest Sciences has a consensus target price of $10.00, indicating a potential upside of 212.50%. Given BioHarvest Sciences' stronger consensus rating and higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Neoleukin Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Neoleukin Therapeutics' return on equity of -37.22% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

BioHarvest Sciences has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
BioHarvest Sciences	$35.16M	1.79	-$11.14M	-$0.59	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BioHarvest Sciences had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for BioHarvest Sciences and 0 mentions for Neoleukin Therapeutics. BioHarvest Sciences' average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
BioHarvest Sciences	Very Positive

Summary

BioHarvest Sciences beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.

How does BioHarvest Sciences compare to MacroGenics?

BioHarvest Sciences (NASDAQ:BHST) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

BioHarvest Sciences has higher earnings, but lower revenue than MacroGenics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.79	-$11.14M	-$0.59	N/A
MacroGenics	$149.50M	1.68	-$74.62M	-$1.10	N/A

In the previous week, MacroGenics had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 3 mentions for MacroGenics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat MacroGenics' score of 0.63 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
BioHarvest Sciences	Very Positive
MacroGenics	Positive

96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioHarvest Sciences currently has a consensus target price of $10.00, suggesting a potential upside of 212.50%. MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 38.89%. Given BioHarvest Sciences' higher possible upside, analysts plainly believe BioHarvest Sciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

BioHarvest Sciences has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

BioHarvest Sciences has a net margin of -32.54% compared to MacroGenics' net margin of -44.79%. BioHarvest Sciences' return on equity of -76.03% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

BioHarvest Sciences and MacroGenics tied by winning 8 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Entrada Therapeutics?

Entrada Therapeutics (NASDAQ:TRDA) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

BioHarvest Sciences has higher revenue and earnings than Entrada Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$5.74M	43.71	-$143.75M	-$3.99	N/A
BioHarvest Sciences	$35.16M	1.79	-$11.14M	-$0.59	N/A

BioHarvest Sciences has a net margin of -32.54% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%
BioHarvest Sciences	-32.54%	-76.03%	-25.30%

Entrada Therapeutics has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, BioHarvest Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

86.4% of Entrada Therapeutics shares are owned by institutional investors. 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entrada Therapeutics presently has a consensus price target of $17.50, indicating a potential upside of 170.90%. BioHarvest Sciences has a consensus price target of $10.00, indicating a potential upside of 212.50%. Given BioHarvest Sciences' higher probable upside, analysts clearly believe BioHarvest Sciences is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Entrada Therapeutics had 4 more articles in the media than BioHarvest Sciences. MarketBeat recorded 5 mentions for Entrada Therapeutics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Entrada Therapeutics' score of 0.27 indicating that BioHarvest Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Entrada Therapeutics	Neutral
BioHarvest Sciences	Very Positive

Summary

Entrada Therapeutics and BioHarvest Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

BioHarvest Sciences (NASDAQ:BHST) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioHarvest Sciences has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market.

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 2 mentions for Fulcrum Therapeutics and 1 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 1.87 beat Fulcrum Therapeutics' score of 0.19 indicating that BioHarvest Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
BioHarvest Sciences	Very Positive
Fulcrum Therapeutics	Neutral

BioHarvest Sciences has higher earnings, but lower revenue than Fulcrum Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$35.16M	1.79	-$11.14M	-$0.59	N/A
Fulcrum Therapeutics	$80M	2.87	-$74.88M	-$1.15	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Fulcrum Therapeutics' return on equity of -27.80% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

BioHarvest Sciences currently has a consensus target price of $10.00, suggesting a potential upside of 212.50%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 137.68%. Given BioHarvest Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe BioHarvest Sciences is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Fulcrum Therapeutics beats BioHarvest Sciences on 9 of the 15 factors compared between the two stocks.

Get BioHarvest Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHST vs. The Competition

Export

Metric	BioHarvest Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$62.77M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-5.42	20.00	24.00	24.42
Price / Sales	1.79	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.46	8.32	10.60	6.82
Net Income	-$11.14M	$23.94M	$3.57B	$337.56M
7 Day Performance	2.56%	1.84%	0.59%	1.16%
1 Month Performance	-21.95%	-0.04%	1.54%	3.16%
1 Year Performance	-55.56%	44.82%	25.41%	30.60%

BioHarvest Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHST BioHarvest Sciences	3.1461 of 5 stars	$3.20 flat	$10.00 +212.5%	-55.6%	$62.77M	$35.16M	N/A	N/A
SRZN Surrozen	3.7704 of 5 stars	$21.52 -11.7%	$42.00 +95.2%	+146.7%	$249.85M	$3.48M	N/A	80
NLTX Neoleukin Therapeutics	N/A	$26.49 -3.6%	N/A	+47.3%	$248.95M	N/A	N/A	90
MGNX MacroGenics	2.5097 of 5 stars	$3.91 -8.0%	$5.50 +40.7%	+160.5%	$248.53M	$149.50M	N/A	430	News Coverage
TRDA Entrada Therapeutics	3.7438 of 5 stars	$6.37 -9.0%	$18.25 +186.5%	-14.9%	$247.29M	$25.42M	N/A	110	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BHST) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioHarvest Sciences (BHST) Competitors

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

How does BioHarvest Sciences compare to Surrozen?

Summary

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Summary

How does BioHarvest Sciences compare to MacroGenics?

Summary

How does BioHarvest Sciences compare to Entrada Therapeutics?

Summary

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioHarvest Sciences (BHST) Competitors

BHST vs. SRZN, NLTX, MGNX, TRDA, and FULC

How does BioHarvest Sciences compare to Surrozen?

Do analysts rate BHST or SRZN?

Which has more risk & volatility, BHST or SRZN?

Does the media prefer BHST or SRZN?

Which has stronger valuation and earnings, BHST or SRZN?

Do institutionals & insiders believe in BHST or SRZN?

Is BHST or SRZN more profitable?

Summary

How does BioHarvest Sciences compare to Neoleukin Therapeutics?

Do analysts prefer NLTX or BHST?

Which has more risk and volatility, NLTX or BHST?

Is NLTX or BHST more profitable?

Which has higher valuation & earnings, NLTX or BHST?

Do insiders and institutionals hold more shares of NLTX or BHST?

Does the media refer more to NLTX or BHST?

Summary

How does BioHarvest Sciences compare to MacroGenics?

Which has better earnings and valuation, BHST or MGNX?

Does the media prefer BHST or MGNX?

Do institutionals and insiders hold more shares of BHST or MGNX?

Do analysts recommend BHST or MGNX?

Which has more volatility and risk, BHST or MGNX?

Is BHST or MGNX more profitable?

Summary

How does BioHarvest Sciences compare to Entrada Therapeutics?

Which has better earnings and valuation, TRDA or BHST?

Is TRDA or BHST more profitable?

Which has more volatility & risk, TRDA or BHST?

Do insiders and institutionals believe in TRDA or BHST?

Do analysts prefer TRDA or BHST?

Does the media refer more to TRDA or BHST?

Summary

How does BioHarvest Sciences compare to Fulcrum Therapeutics?

Do insiders & institutionals hold more shares of BHST or FULC?

Which has more volatility & risk, BHST or FULC?

Does the media prefer BHST or FULC?

Which has stronger earnings & valuation, BHST or FULC?

Is BHST or FULC more profitable?

Do analysts recommend BHST or FULC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHST vs. The Competition

BioHarvest Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools